参考文献: 1. Hanicki Z. 1988. Pol Arch Med Wewn, 80: 290-3. 2. Haniu M, Narhi LO, Arakawa T, et al. 1993. Protein Sci, 2: 1441-51. 3. Baranowska-Daca EandKsiazek A. 1994. Ann Univ Mariae Curie Sklodowska Med, 48 Suppl 3: 51-60. 4. Chow KM, Szeto CC, Li PK. 2003. Am J Kidney Dis, 41: 266-7; author reply 7. 5. Maurer MH, Schabitz WR, Schneider A. 2008. Curr Med Chem, 15: 1407-11.
Gene IDs: 2056
纯度: > 98 % by SDS-PAGE and HPLC analyses.
内毒素水平: Less than 0.01 EU/μg of Recombinant HumanEPO-α as determined by LAL method.
活性: Fully biologically active when compared to standard. The Specific Activity was measured by the stimulation of reticulocyte production in normocyth-aemic mice and is no less than 1.5 × 105 IU/mg.
溶解方法: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
形态: Lyophilized from a 0.2 μm filtered concentrated solution in sodium citrate buffer (1 liter of ddH2O containing 5.9 g of sodium citrate, 5.8 g of sodium chloride and 0.06 g of citric acid).
储存/保存方法: This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.